

Applicants: Philip O. Livingston and Friedhelm Helling
Serial No.: 08/196,154
Filed : November 16, 1995
Page 2

material is in brackets and the inserted material is underlined is
attached hereto as Exhibit A:

J
--88. (Amend) The composition of claim 78, wherein the amount
of the saponin is an amount between about 10 ug and about
200 ug.--

SVB
R3
J2
--94. (Amended) A method of treating a cancer in a subject
which comprises administering to the subject an effective
cancer treating amount of a composition which comprises:
a) a conjugate of i) a GM2 or GD2 ganglioside
derivative which comprises an unaltered
oligosaccharide part and an altered ceramide
portion, to ii) Keyhole Limpet Hemocyanin;
b) a saponin derivable from the bark of a Quillaja
saponaria Molina tree; and
c) a pharmaceutically acceptable carrier;
the relative amounts of such conjugate and such saponin
being effective to stimulate or enhance antibody
production in the subject,
wherein in the conjugate the ganglioside derivative is
conjugated to Keyhole Limpet Hemocyanin through a
ceramide-derived carbon of the ganglioside derivative to
Keyhole Limpet Hemocyanin, so as to thereby treat the
cancer in the subject.--

--95. (Amended) The method of claim 94, wherein the cancer is
of epithelial origin.--

--96. (Amended) The method of claim 94, wherein the cancer is

4